Compare Abeona Therapeutics Inc (ABEO) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs TG Therapeutics Inc — how do they compare? Abeona Therapeutics Inc trades at $6.76 (market cap $373.32M), while TG Therapeutics Inc trades at $56.6 (market cap $8.89B). The key difference: TG Therapeutics Inc is far larger — about 23.8× Abeona Therapeutics Inc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Abeona Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | TGTX | |
|---|---|---|
Market Cap | $373.32M | $8.89B |
Sector | Health | Health |
52-Week High | $7.23 | $58.06 |
52-Week Low | $4.17 | $26.39 |
Enterprise Value | $228.22M | $9.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
TGTX trades at $55.47, up 4.05% today, with a bullish technical signal from moving averages and strong fundamental profitability. Revenue grew to $616.29M in 2025 with a net income margin of 65.95%, though recent quarterly EPS missed expectations. Positive news includes a new Phase II study for Briumvi in schizophrenia and strong sales momentum.
Outlook is positive driven by Briumvi's expansion, but risks include clinical trial outcomes and earnings volatility. Analysts are bullish with 84.6% buy ratings. The stock's high valuation multiples warrant monitoring of execution against growth expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
